ALPL Knockout Cell Line (HEK 293)

The choice depends on whether you are studying ALPL (tissue-nonspecific alkaline phosphatase, TNAP)'s role as the principal regulator of extracellular pyrophosphate or modeling hypophosphatasia (HPP). The Knockout line is the standard tool for asking whether ALPL is required for these processes — ALPL is the tissue-nonspecific alkaline phosphatase isoform (versus tissue-specific intestinal, placental, germ cell isoforms) expressed in bone, liver, kidney, and other tissues; ALPL hydrolyzes inorganic pyrophosphate (PPi) into inorganic phosphate, promoting bone mineralization (PPi is an inhibitor of hydroxyapatite formation); ALPL also dephosphorylates pyridoxal-5'-phosphate, LPS, and other substrates. Overexpression is useful for studying ALPL gain-of-function effects. For skeletal disease research, the EDITGENE ALPL Knockout in HEK293 is uniquely valuable — ALPL biallelic loss-of-function mutations cause hypophosphatasia (HPP), a rare metabolic bone disease with spectrum of presentations from perinatal lethal to adult dental forms. Rescue with wild-type or patient-derived ALPL mutations enables disease modeling. The knockout is a critical specificity tool for ⭐ asfotase alfa (Strensiq, FDA-approved enzyme replacement therapy for perinatal/infantile/juvenile-onset HPP), and emerging ALPL-targeted therapeutics.

Primary applications: • Extracellular pyrophosphate: PPi quantification in ALPL-null cells. • HPP modeling: rescue with patient-derived ALPL mutations (e.g., E191K, R206G, others) for genotype-function studies of perinatal/infantile/adult HPP forms. • Asfotase alfa pharmacology: in heterologous HPP-relevant contexts, asfotase alfa-mediated PPi hydrolysis restoration. • Substrate dephosphorylation: pyridoxal-5'-phosphate (PLP) and LPS dephosphorylation analysis given ALPL's broad substrate spectrum. EDITGENE recommends this model for researchers investigating HPP disease mechanisms and asfotase alfa pharmacology.

Yes. ALPL rescue experiments are well-established for HPP research: • Construct design: use a codon-modified ALPL sequence with a small intracellular tag — ALPL is a GPI-anchored extracellular ectoenzyme; tags should preserve GPI processing and surface expression. • Surface localization validation: confirm GPI-anchored plasma membrane localization by cell surface staining. • Catalytically-dead rescue: active site Zn²⁺-binding mutations abolish alkaline phosphatase activity. • HPP mutation rescue: patient-derived ALPL mutations (E191K, R206G, others) enable disease modeling. • Functional readout: rescue should restore PPi hydrolysis and pNPP/MUP substrate cleavage activity. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.